ANGELINI PHARMA BROADENS ITS HPAPI CDMO CAPABILITIES
Click HERE to download the PDF
HPAPI drugs make up a growing percentage of the small molecule drug development pipeline in the global pharmaceutical industry today. The percentage of HPAPI drug candidates in the clinical development is rising steadily, owing to the rapid growth in small molecule cytotoxic compounds and antibody drug conjugates (ADCs) targeted therapies for oncology indications. Additional therapeutic areas in the HPAPI space include respiratory, hormonal, cardiovascular, and central nervous system disorders, among others. Overall, cancer drugs as a class account for the greatest share of the global HPAPI market. The oncology-focus R&D pipeline growth and increase in adoptation of open & virtual innovation model by pharma R& ... ...